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Abstract 
Calcipotriol, a vitamin D analogue, and betamethasone dipropionate, a high potency corticosteroid, 
are complementary agents for the topical treatment of psoriasis vulgaris. Robust evidence on the 
efficacy and safety of their fixed combination has been provided by randomized, double-blind, 
controlled clinical trials involving more than 7000 patients with the ointment formulation in 
psoriasis of the body and more than 4000 patients with the gel formulation in scalp psoriasis. These 
trials have shown that the fixed combination ointment is more effective and better tolerated, not 
only than placebo, but also than calcipotriol and tacalcitol monotherapies. In addition, it has proved, 
in most instances, to be more effective than betamethasone and at least as well tolerated. The same 
applies to the gel for scalp and body psoriasis. Safety studies have excluded that repeated courses of 
treatment with the fixed combination for up to one year produce systemic effects. Studies have also 
shown that the fixed combination treatment improves quality of life to a significantly greater extent 
than calcipotriol, with the once daily regimen most appreciated by patients, in both active disease 
and recurrency. Because of the extensive evidence, American and European guidelines recommend 
the calcipotriol/betamethasone dipropionate fixed combination as first line topical treatment for 
mild to moderate plaque psoriasis of the body and scalp. 
 
